Mar 08, 2019 7:05am EST IMV Inc. to Announce 2018 Fourth Quarter and Fiscal Year-End Results and Host Investor Conference Call and Webcast on March 22, 2019
Mar 07, 2019 7:05am EST IMV Inc. to Present at the Cowen and Company 39th Annual Health Care Conference
Feb 28, 2019 4:51pm EST IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares
Jan 29, 2019 7:05am EST IMV Announces Clinical Update for DPX-Survivac Program in Ovarian Cancer Following Positive Feedback from U.S. FDA
Jan 17, 2019 7:05am EST First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients
Dec 13, 2018 4:05am EST IMV Inc. Presents Updated Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ESMO Immuno-Oncology Congress
Dec 10, 2018 7:05am EST IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac’s Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018
